XML 26 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
The Company and Summary of Significant Accounting Policies (Details) (USD $)
 1 Months Ended 3 Months Ended 12 Months Ended 147 Months Ended 1 Months Ended 3 Months Ended
Mar. 04, 2013
Mar. 31, 2014
Patients
Mar. 31, 2013
Dec. 31, 2013
Mar. 31, 2014
Mar. 31, 2014
Feb. 28, 2014
Two Zero One Four Equity Financings
Registered Direct Offering
Mar. 31, 2014
Phase 3 heart failure (HF) trial of Gencaro
Patients
Company Development Stage and Basis of Presentation (Textual) [Abstract]                
Number of patients               2,708
Number of patients company plans to enroll   200           420
Number of years to complete the study   2 years 6 months            
Loss from operations   $ (2,390,000) $ (1,070,000)   $ (108,500,000) $ (108,473,000)    
Cash flows from operations         (106,400,000)      
Fund raised through sale of convertible preferred and common stock       19,300,000   10,841,000    
Proceeds from the issuance of common stock   $ 9,018,000 $ 1,741,000     $ 24,868,000 $ 7,900,000  
Reverse stock split 1-for-6 reverse split